[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Belgian Research on AIDS and HIV Consortium\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100548743",false,"NCT06424964","Use of Long-Acting Injectable Cabotegravir\u002FRilpivirine for the Treatment of HIV in Belgium","Inclusion Criteria:\n\n* HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB\u002FRPV between September 1, 2021, and March 31, 2024.","ALL","18 Years","99 Years",{"count":18,"type":19},600,"ESTIMATED","OBSERVATIONAL","This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.\n\nPrimary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir\u002Frilpivirine (CAB\u002FRPV) for the treatment of HIV\n\nSecondary outcomes\n\n• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis",[23],"Human Immunodeficiency Virus","RECRUITING","2025-02-04",{"date":27,"type":28},"2025-02-05","ACTUAL",{"date":30,"type":28},"2025-01-13",{"date":32,"type":19},"2025-07",{"name":34,"class":35},"Belgian Research on AIDS and HIV Consortium","OTHER",""]